Development of an AAV9-RNAi-mediated silencing strategy to abrogate TRPM4 expression in the adult heart

The cation channel transient receptor potential melastatin 4 (TRPM4) is a calcium-activated non-selective cation channel and acts in cardiomyocytes as a negative modulator of the L-type Ca2+ influx. Global deletion of TRPM4 in the mouse led to increased cardiac contractility under β-adrenergic stimulation. Consequently, cardiomyocyte-specific inactivation of the TRPM4 function appears to be a promising strategy to improve cardiac contractility in heart failure patients. The aim of this study was to develop a gene therapy approach in mice that specifically silences the expression of TRPM4 in cardiomyocytes. First, short hairpin RNAmiR30 (shRNAmiR30) sequences against the TRPM4 mRNA were screened in vitro using lentiviral transduction for a stable expression of the shRNA cassettes. Western blot analysis identified three efficient shRNAmiR30 sequences out of six, which reduced the endogenous TRPM4 protein level by up to 90 ± 6%. Subsequently, the most efficient shRNAmiR30 sequences were delivered into cardiomyocytes of adult mice using adeno-associated virus serotype 9 (AAV9)-mediated gene transfer. Initially, the AAV9 vector particles were administered via the lateral tail vein, which resulted in a downregulation of TRPM4 by 46 ± 2%. Next, various optimization steps were carried out to improve knockdown efficiency in vivo. First, the design of the expression cassette was streamlined for integration in a self-complementary AAV vector backbone for a faster expression. Compared to the application via the lateral tail vein, intravenous application via the retro-orbital sinus has the advantage that the vector solution reaches the heart directly and in a high concentration, and eventually a TRPM4 knockdown efficiency of 90 ± 7% in the heart was accomplished by this approach. By optimization of the shRNAmiR30 constructs and expression cassette as well as the route of AAV9 vector application, a 90% reduction of TRPM4 expression was achieved in the adult mouse heart. In the future, AAV9-RNAi-mediated inactivation of TRPM4 could be a promising strategy to increase cardiac contractility in preclinical animal models of acute and chronic forms of cardiac contractile failure. Supplementary Information The online version contains supplementary material available at 10.1007/s00424-021-02521-6.


Introduction
TRPM4 is a Ca 2+ -activated, non-selective cation channel whose expression has been detected in the human heart as well as in the atrium and ventricle of the mouse [18,22]. In humans, gain-of-function mutations of the Trpm4 gene are strongly associated with familial arrhythmia syndromes such as Brugada syndrome and progressive familial heart block type I [17,20,35]. Previous studies showed that TRPM4deficient mice have an increased β-adrenergic response compared to wild-type mice [23]. In pressure-volume (PV-loop) measurements, β-adrenergic stimulation with isoproterenol (ISO) resulted in an increased left ventricular contractility compared to control animals. In vitro studies on isolated cardiomyocytes indicated that TRPM4 deficiency is associated with a faster repolarization of the action potential and an increased Ca 2+ influx via L-type channels with isoproterenol stimulation [23]. Recently, we could show that the increased ISO-evoked inotropy and elevated Ca 2+ transient can only be observed in TRPM4-deficeint mice on the 129SvJ genetic background and the TRPM4 protein expression level is about 80% higher in wild-type 129SvJ mice than in mice with C57B/6N background [26]. The results of this study indicate that the relevance of TRPM4 for cardiac contractility depends on homeostatic TRPM4 expression levels or the genetic background of different mouse strains. Studies of cardiac contractility on isolated left ventricular papillary muscles also showed an increased contractile force in the papillary muscle of TRPM4 -/mice compared to wild-type controls under βadrenergic stimulation [37]. In the same study, it was additionally observed that the activation of adenylate cyclase in the papillary muscle of the TRPM4 -/mouse resulted in a stronger contraction force than in papillary muscles of wild-type controls. In summary, both studies suggest that TRPM4 reduces the driving force for Ca 2+ to enter cells via the L-type Ca 2+ channels [23,37]. From a translational point of view, inactivating cardiac TRPM4 function in cardiomyocytes is a promising approach to increase the ventricular contractility of the heart. Blocking cardiac TRPM4 function, especially at elevated catecholamine levels, as they occur in patients with chronic heart failure, could lead to an improvement in cardiac function. So far, there are no small compounds blocking TRPM4 channels with sufficient specificity. However, if such TRPM4 blockers existed, adverse effects could be expected from ubiquitous TRPM4 inactivation arising from other TRPM4-expressing cell types. Blocking the TRPM4 channel in chromaffin cells of the adrenal medulla could lead to hypertension, in mast cells to increased release of proinflammatory substances, and in immune cells to increased activation [22,38]. Therefore, molecular inhibition of TRPM4 biosynthesis using RNA interference (RNAi) in combination with viral vector delivery to defined cell types is a suitable alternative to modify TRPM4 function in selected organ functions. Today, targeted RNAi strategies not only are used in basic research to downregulate gene expression, but also are becoming increasingly important for therapeutic use to inhibit expression of pathological relevant genes by harnessing the endogenous RNAi processing pathway [1,13]. Classical short hairpin RNAs (shRNAs) under the control of strong RNA Pol III promoters can lead to saturation of the endogenous miRNA processing pathway, resulting in downregulation of endogenous miRNAs that fulfill vital functions [9,11]. shRNAs embedded in an miRNA background (shRNA miR ) enable the shRNA sequence to be transcribed efficiently by a tissue-specific RNA Pol II promoter. In contrast to Pol III promoter-driven shRNAs, less toxic effects were observed when using shRNA miR constructs [5,24]. This may be due to weaker RNA Pol II promoters, which lead to a lower expression level of the shRNA miR cassette. Overall, the artificial shRNA miR has an improved safety profile compared to classic shRNA, which is particularly important for gene therapy approaches. Because of the short DNA sequence and the simple design, shRNA and shRNA miR expression cassettes can be packaged in AAV vectors to ensure stable and long-term expression in non-dividing cells [10]. For targeting of the myocardium in rodents, the AAV serotype 9 is particularly well suited after intravenous administration via the tail vein, evidenced by the finding that an AAV9 dose of 10 11 vector genome copies per mouse typically results in robust transduction of over 90% of the cardiomyocytes in the mouse heart [14,34]. However, it should be noted that AAV9 transduction is not limited to cardiomyocytes, and that other organs including the liver and brain can also be transduced to a high extent [43]. By using a cardiomyocyte-specific promoter, expression can be further restricted to cardiomyocytes [27,32,34,41].
The aim of our work was to develop a highly efficient therapeutic AAV9-RNAi strategy to abrogate TRPM4 expression in the adult heart.

Plasmid construction
Four commercially available shTRPM4 miR30 (#1-#4) constructs from Thermo Scientific (USA) were selected and delivered in a lentiviral pGIPZ vector. shTRPM4 mir-30 sequences (Table S1) were flanked by recognition sites for the restriction enzymes XhoI (5′) and MluI (3′), to facilitate an exchange of the specific stem sequences. Two additional shTRPM4 mir-30 (#5-# 6) constructs were generated. Their sequences were derived from commercially available shRNAs (shRNA-#5 -TRCN0000068684, shRNA-#6 -TRCN0000068687, Sigma, USA), and the sequence of shRNA #5 has already been shown to mediate robust downregulation of TRPM4 in mouse cells [29,30]. The stem sequences of the two shRNAs were synthesized and cloned into the pGIPZ vector via a directed ligation using the flanking restriction enzyme recognition sites XhoI (5′) and MluI (3′). In a negative control vector, the shRNA miR30 sequence was removed using XhoI and MluI.

Generation and quantification of AAV9 viral particles
Recombinant AAV9 (rAAV9) vector particles were generated and purified using the iodixanol gradient ultracentrifugation method [8,44]. The rAAV9 production was carried out using HEK293T cells. First, 1.8 × 10 8 HEK293T cells were seeded in a ten chamber CellStack® (Corning, USA) and cultured in DMEM+Glutamax (Gibco, Thermo Fisher Scientific, USA) supplemented with 10% fetal bovine serum (FBS) and 1% Pen/Strep. After 48 h, a 1:1 molar ratio of rAAV vector plasmid and the rep-cap AAV9 helper plasmid (pDP9rs) was mixed and transfected using polyethyleneimine (PEI). The cells were harvested in 3 ml lysis buffer and lysed by four freeze-thaw cycles 72 h after transfection. The vector particles were purified using an iodixanol gradient consisting of four phases with decreasing density (60%, 40%, 25%, 15%) and ultracentrifugation at 50.000g for 135 min at 4°C. Approximately 3 ml of the 40% phase, in which predominantly full virus particles accumulate, was recovered with a 27G needle. Finally, the vector solution was buffered into PBS using dialysis tubes (Zeba Spin Desalting Columns 7K MWCO, Thermo Scientific, USA) and concentrated (VivaSpin 10K MWCO, Sartorius, Germany). Vector titer was determined by quantifying vector genomes using a qPCR SYBR-Green assay (Biorad) and primers listed in Table S2 [16].

Mouse experiments and genotyping
Experimental procedures were approved by the Regierungspräsidium Karlsruhe according to the Tierschutzgesetz (T-64/18, G-89/15). TRPM4-deficient mouse lines were described previously [38] and housed at the Interfaculty Biomedical Faculty (IBF) Heidelberg. Mice were kept under specified pathogen-free conditions on a 12-h light/12-h dark cycle with water and standard food (Rod18, LASvendi GmbH, Germany) available ad libitum. Injections of AAV9 at 3 × 10 12 vector genomes per mouse (vg/mouse) were performed in 3-week to 8-week-old male mice. Tail vein (TV) injections were performed in conscious-restrained mice by injecting 200 μl vector solution into the lateral vein. Retroorbital sinus injections of 100 μl vector solution were performed in anesthetized mice using 2% isoflurane. Genotyping of mice carrying a trpm4 − (null) allele, a trpm4flox allele [38], and the a-MHC-Cre ERT2 transgene [36] and their wild-type siblings was carried out by PCR using the primer pairs listed in Table S2. To obtain template genomic (g)DNA, ear biopsies were taken and transferred into 97.5 μl of DirectPCR buffer (Viagen, USA) supplemented with 2.5 μl proteinase K (10 mg/ml, AppliChem, Germany) and lysed overnight at 55°C. Proteinase K was denatured for 45 min at 85°C. Taq PCR (0.3 μl Taq DNA Polymerase (lab made), 1x reaction buffer (100 mM Tris pH 8.3, 15 mM MgCl 2 , 500 mM KCl), 200 μM dNTPs, 500 nM primer forward and reverse and 1.0 μl gDNA) was performed using the following PCR protocol: 94°C 30 s denaturation, 35 cycles of denaturation at 94°C for 10 s, annealing at 58°C for 30 s, and elongation at 72°C for 30 s.

Droplet digital PCR
Droplet digital PCR (ddPCR) was carried out to determine the AAV genome copy number per host genome using the Magel2 gene as a diploid reference [28]. Primers and an FAM-labeled probe specific for the bGHpA (bovine growth hormone polyadenylation signal) sequence were used to determine the AAV genome copies (Table S2). Primers and an HEX-labeled probe were designed to determine the reference Magel2 gene copy number (Table S2).
Genomic DNA (gDNA) from the heart, liver, and skeletal muscle (musculus vastus lateralis) was isolated and purified by DNAeasy Blood and Tissue kit (Qiagen, USA), and then digested with HindIII (New England Biolabs, USA) for 1 h at 37°C. ddPCR multiplex master mix was prepared by adding 11 μl 2 × Supermix for Probes (no UTPs) (Bio-Rad, USA), 1.1 μl 900 nM forward and reverse primers, 1.1 μl bGHpA Probe (250 nM), 1.1 μl Magel2 Probe (250 nM), 3.3 μl digested gDNA (7.5 ng/μl), and 3.3 μl ddH2O. Droplets were generated using a QX200 Droplet Generator (Bio-Rad, USA) according to the manufacturer's protocol. The resulting droplets were transferred to a 96-well PCR plate (Thermos Scientific, USA) and end point PCR was performed using a C1000 Touch PCR thermal cycler (Bio-Rad) and the following PCR program: 95°C for 5 min, 30 cycles of 95°C for 30 s and 54°C for 60 s, 4°C for 5 min, 90°C for 5 min, and then cooling down to 4°C. Fluorescence FAM and HEX signals of end point PCR products were analyzed using the QX200 droplet reader (Bio-Rad, USA) and the gene copy numbers were analyzed using the QuantaSoft™ software (Bio-Rad, USA, version 1.7.4.0917). The AAV genome copy number per host genome was calculated as follows: bGHpA positive droplets/(agel2 positive droplets/2).

Statistical analysis
Statistical analysis was performed using OriginPro 8.5 and Excel 2010. Data are expressed as mean ± standard deviation (SD). Statistical significance between the two groups was tested using a two-sample t-test: ***p < 0.0001, **p < 0.001, *p < 0.05.

Results
Maximum achievable myocardial TRPM4 protein knockdown: evaluation in Trpm4 fx/fx /αMHC-Cre ERT2 mice We reasoned that complete inactivation of the Trpm4 expression in cardiomyocytes via Cre-LoxP-mediated gene deletion represents the most useful indicator for a maximum achievable TRPM4 protein knockdown in ventricular tissue. Provided that a specific antibody is available, the easiest way to estimate the amount of protein present is by Western blotting. Our experience from analysis of other low abundant membrane proteins including TRPM4 tells that a membrane protein fraction must first be prepared from cells or tissues before running these proteins on SDS-PAGE and blotting them onto a membrane for reliable detection and quantification.
For the induction of the αMHC-Cre ERT2 recombinase, tamoxifen was administered intraperitoneally once a day on 5 consecutive days to 6-week-old Trpm4 flox/flox /αMHC-Cre ERT2-positive mice (Fig. 1a). Trpm4 flox/flox /αMHC-Cre ERT2-negative siblings served as controls and were also treated with tamoxifen. A reduction in TRPM4 protein levels was observed in ventricular microsomal membrane fractions of αMHC-Cre ERT2-positive animals already 2 weeks after the last tamoxifen injection (Fig. 1b). Quantitative Western blot analysis in samples of three Cre-negative and six Cre-positive mice showed a TRPM4 reduction of 90 ± 1% in mice with induction of Cre expression in cardiomyocytes (Fig. 1c). Assuming efficient Cre-mediated recombination in cardiomyocytes, the remaining TRPM4 proteins must originate from cardiac cells other than cardiomyocytes, for example from cardiac fibroblasts and endothelial cells [36]. The result shown in Fig. 1b-c therefore suggests that a 90% reduction of TRPM4 is the maximum level that can be achieved by the intended knockdown approach.

Evaluation of different shTRPM4 miR30 sequences in vitro
To achieve a specific reduction of TRPM4 protein expression with the help of an RNAi strategy, four different commercially available microRNA-30-based shRNAs (shTRPM4 miR30 ) targeting murine TRPM4 were chosen. The shTRPM4 miR30 sequences were purchased from Thermo Scientific Open Biosystems in the lentiviral pGIPZ vector (Fig. 2a). In addition, two classic shRNA sequences (shRNA miR30 #5 and #6, Table S1) were tested based on previously published work [29,30] and cloned into the lentiviral pGIPZ backbone. In order to evaluate their TRPM4 knockdown potential, individual shTRPM4 miR30 sequences were subsequently tested in murine B16F10 cells. Screening of various cell lines regarding TRPM4 expression revealed that murine B16F10 cells do endogenously express TRPM4 proteins (Fig. 2c). All pGIPZ-shTRPM4 miR30 constructs as well as a pGIPZ control construct, in which the shTRPM4 miR30 cassette was removed, were packaged into lentiviral particles (Fig. 2a). The B16F10 cells were seeded at 100.000 cells per well and transduced 24 h later with a multiplicity of infection (MOI) of 1 (Fig. 2b). All pGIPZ-shTRPM4 miR30 constructs contained a puromycin resistance cassette and selection was performed 6 days after transduction using puromycin (1 μg/ml). According to a FACS analysis, more than 99% of cells were GFP-positive on day 13 after selection ( Fig. 2b and Fig. S1). Such cultures of B16F10 cells expressing the individual pGIPZ-shTRPM4 miR30 constructs were expanded for Western blotting.
Myocardial TRPM4 knockdown obtained by a singlestranded AAV9-CMV-shTRPM4 miR30 -tandem construct To use the shTRPM4 miR30 constructs for TRPM4 knockdown in murine hearts, the constructs were transferred to an adenoassociated virus (AAV) vector system, and packaged as AAV serotype 9 that leads to highest transduction efficiency in cardiomyocytes when applied at doses of 1 × 10 11 -1.8 × 10 12 vg/mouse via the lateral tail vein [14,31,34]. For the RNAi-based reduction of TRPM4, high cardiac transduction efficiency as well as a high AAV9 copy number per cardiomyocyte should be achieved by the application of 3 × 10 12 vg/ mouse.
For the AAV9-mediated shTRPM4 miR30 transfer into the mouse heart, an AAV vector was cloned, which contained the t w o m o s t p r o m i s i n g s h T R P M 4 m i R 3 0 s e q u e n c e s (shTRPM4 miR30 -#3 and shTRPM4 mir30 -#4) as a tandem construct (termed "shTRPM4 miR30 -tandem") under the control of the cardiomyocyte-specific MLC260 promoter (Fig. 3a, upper  panel). Based on the size of the expression cassette and the packaging limit of AAV, a single-stranded AAV vector (ssAAV) had to be used. Fig. 1 Evaluation of maximum achievable myocardial TRPM4 protein knockdown in cardiomyocyte-specific TRPM4 knockout mice. a Course of tamoxifen treatment in TRPM4 fx/fx /αMHC-Cre ERT2-postive and TRPM4 fx/fx /αMHC-Cre ERT2-Cre negative mice. b Western blot analysis with anti-TRPM4 and anti-Calnexin 2 weeks after tamoxifen injections.
c Quantification of the relative TRPM4 protein level in the heart of TRPM4 fx/fx /αMHC-Cre ERT2-positive (Cre+) mice in comparison to TRPM4 fx/fx /αMHC-Cre ERT2-negative (Cre − ) mice. Relative protein level of TRPM4 is expressed as mean ± SD. ***p <0.005 Six 8-week-old male wild-type mice were treated with 3 × 10 12 vg/mouse of the shTRPM4 miR30 -tandem construct. The vector was administered as single intravenous injection to the tail vein. As a control group, four untreated siblings were used, which were kept under the same conditions as the AAV9-treated mice. Western blot analysis of TRPM4 protein expression from microsomal membrane fractions of the myocardium was carried out 11 weeks after AAV9 application (Fig. 3b). Examination of the TRPM4 levels in the heart showed a significant reduction of 46 ± 17% in TRPM4 protein expression in the AAV9-shTRPM4 miR30 -tandem-treated mice compared to untreated siblings (Fig. 3b-c).
Self-complementary scAAV9-CMV-shTRPM4 miR30tandem-mediated knockdown of TRPM4 in the myocardium of the mouse Since the ssAAV-shTRPM4 miR30 -tandem construct did not achieve a sufficiently high knockdown efficiency, we considered to use a self-complementary AAV (scAAV) that is often  2 kb), the WPRE sequence, the IRES, and the reporter gene used in the previous construct were omitted. In addition, the cardiac MLC260 promoter was replaced by the enhanced human CMV promoter (Fig. 3a, middle panel), which is considered to convey higher expression levels in mouse cardiomyocytes [27]. In an alternative approach using the same vector backbone, an expression cassette consisting of three different classic shRNAs (shTRPM4-#7, shTRPM4-#8, and shTRPM4-#4) against TRPM4 under the control of three different RNA Pol III promoters was cloned (Fig. 3a, lower panel). In this construct, shTRPM4-#4 has the same sense sequence as in shTRPM4 mir30 -#4, which achieved 90% TRPM4 reduction in B16F10 when expressed after lentiviral transduction. The other two shRNAs (shTRPM4-#7, shTRPM4-#8) were generated via the online program siRNA Wizard and Block-it RNAi Designer.
The two experimental groups were treated with scAAV9-shTRPM4-triple and scAAV9-shTRPM4 miR30 -tandem vector particles, respectively. Four to five 8-week-old male mice were treated with 3 × 10 12 vg/mouse, and four to five untreated siblings served as controls. Vectors were again applied by single intravenous injection via the tail vein. Analysis of TRPM4 protein expression was carried out 11 weeks after AAV9 application. Microsomal membrane proteins were prepared from hearts and the TRPM4 protein levels were analyzed by Western blotting. Densitometric evaluation of the antibody stain intensities showed a significant reduction in TRPM4 protein expression by 50 ± 7% in the heart of mice treated with the scAAV9-shTRPM4 mir30 -tandem vector (Fig. 3d-e) and by 46 ± 16% when treated with the scAAV9-shTRPM4-triple ( Fig. 3fg) vector compared to untreated controls.
To further study the kinetics and longevity of shTRPM4 miR30 -tandem expression and TRPM4 knockdown, animals treated with additional scAAV9-shTRPM4 mir30 -tandem production batch 2 and 3 were analyzed at a later time point, 16 weeks after AAV9 application (Fig. 4), using Western blotting (Fig. 4b) to evaluate whether the TRPM4 reduction would be even more pronounced after extended shRNA expression. Indeed, densitometric analysis 16 weeks after AAV application showed a downregulation of TRPM4 expression by 61 ± 9% in scAAV9-shTRPM4 mir30tandem treated mice compared to untreated siblings (Fig. 4c).
Optimization of the scAAV9-CMV-shTRPM4 miR30tandem-mediated knockdown of TRPM4 in the myocardium of the mouse Next, we studied the routes of AAV9 application and compared tail vein injection with AAV9 injection via the retroorbital venous plexus. In a pilot study, mice in both experimental groups were treated with 1 × 10 11 vg/mouse of a scAAV9-eGFP vector (Fig. 5a). Four weeks later, transduction efficiency was assessed using a droplet digital PCR (ddPCR) copy number variation assay using gDNA of the heart and other organs with high AAV9 tropism (Fig. 5c-g). The transduction efficiency was calculated by quantifying bGHpA (Fig. 5c) and Magel2 sequences (Fig. 5d) to determine AAV viral genome and host genome copies, respectively. The analysis of normalized viral genome copies indicated that AAV application via the retro-orbital sinus yielded a 2fold higher transduction efficiency (1.2 AAV copies/host genome) in the myocardium, compared to tail vein injections in which 0.6 AAV copies/host genome were detected (Fig. 5e). In addition, the viral load in the liver, the organ with the highest AAV9 tropism, was significantly reduced by retro-orbital application (7.8 AAV copies/host genome) compared to tail vein injections (12.4 AAV copies/host genome, Fig. 5f), while the route of application showed no significant difference in skeletal muscle transduction (Fig. 5 g).
We then injected juvenile wild-type mice showing high cardiac transduction efficiency with the scAAV9-shTRPM4 miR30 -tandem construct via the retro-orbital sinus. As an AAV9 transduction control, siblings were treated with a scAAV9-eGFP in the same way (Fig. 5h). As before, the mice were analyzed 16 weeks after AAV9 application (Fig.  5i). Hearts were subjected to microsomal membrane purification and TRPM4 protein expression was analyzed by Western blotting (Fig. 5j). Densitometric analysis showed a significant reduction in TRPM4 protein levels by 90 ± 7% in mice treated with scAAV9-CMV-shTRPM4 mir30 -tandem compared to siblings treated with the scAAV9-eGFP control (Fig. 5k).

Discussion
Heart failure represents one of today's largest global health problems and improved therapy options are urgently required. In light of the recent clinical success of several gene therapies for monogenic diseases, cancer gene therapy is primed to be a most promising future option for the treatment of heart failure [7,33,42]. Target molecules for this include regulators of myocardial Ca 2+ signaling, which is often derailed in the failing heart. Several previous studies have indicated that activation of the TRPM4 cation channel in cardiomyocytes negatively modulates the L-type Ca v channel-mediated Ca 2+ influx. Global knockout of TRPM4 in mouse led to increased cardiac contractility under β-adrenergic stimulation, both under basal conditions and after induced myocardial infarction [15,23,37]. This raised the hypothesis that inhibition of TRPM4 in the heart could lead to an increase in cardiac contractility in patients with elevated catecholamine levels. So far, no specific low molecular weight TRPM4 blockers are available. Since TRPM4 is expressed not only in cardiomyocytes but also in many other cells, the use of such blockers might lead to severe adverse drug effects, such as increasing arterial blood pressure [22], triggering an anaphylactic reaction through the release of pro-inflammatory factors from mast cells [38], and increasing activation of immune cells such as dendritic cells [2] or T cells [19,40]. Therefore, gene transfer of an RNAi sequence using recombinant AAV9 vectors to specifically target the TRPM4 transcript in cardiomyocytes may be a safer strategy. Cardiomyocytes can be transduced with high efficiency using AAV9 vectors and, with the help of cardiomyocyte-derived promoters in the corresponding vectors, the expression and the associated knockdown of TRPM4 can be confined to the contractile myocardium with only limited expression in other organs even when AAV particles are applied systemically [27,41].
In this work, specific shRNA miR30 sequences against the mRNA of the murine TRPM4 and distinct vector designs were evaluated. These included a microRNA-based RNAi design, which has an advantageous safety profile with respect to oversaturation of miRNA processing pathway [5,9] and can also be expressed by tissue-specific promoters as a multi-shRNA miR30 transcript [39].
At the beginning of our study, various shRNA miR30 sequences were screened in vitro for their efficiency in degrading the murine Trpm4 mRNA and in thus causing TRPM4 knockdown. We used the murine cell line B16F10, because they were found to exhibit sufficiently high endogenous expression of TRPM4 proteins for our screening of knockout approach with shRNA miR30 constructs. Compared to cardiomyocytes or heart tissue, the B16F10 cells are available in unlimited amounts or can be expanded indefinitely. This is important because for a reliable quantitative determination of TRPM4 protein levels using Western blotting, membrane protein fractions of B16F10 cells must first be prepared. In order to avoid a dilution of the knockdown effect after several rounds of cell division, as would have been the case with transient transfection approaches as well with an AAV6mediated gene transfer in which the transgene is not transmitted to daughter cells, the shRNA miR30 constructs were packaged as lentiviruses. The benefit is that transduction with lentiviral vectors leads to stable integration of the transgene cassette into the host genome. The lentiviral approach has the additional advantage that daughter cells also carry the transgenic information and that the transduced cells can be expanded. In addition, the transgenic cassette contained a puromycin resistance gene, which allowed for a depletion of nontransduced cells before expansion. As a result, despite a low initial transduction efficiency, cells that expressed the shRNA miR30 construct could be specifically expanded and analyzed, which alleviated the expression analysis of low abundant TRPM4 proteins. Using the lentiviral-based in vitro screen, we identified three shRNA miR30 sequences from a total of six, which reduced the endogenous TRPM4 protein level by up to 90 ± 6%.
The primary goal of this work was to downregulate the TRPM4 protein level in the adult murine heart to a maximum extent that is comparable to complete gene deletion as obtaine d b y C r e -l o x P -d e p e n d e n t T R P M 4 d e l e t i o n i n cardiomyocytes. The two most potent shRNA miR30 sequences from the in vitro screen were therefore selected for an in vivo TRPM4 knockdown strategy suitable for therapeutic approaches and subcloned as a tandem construct under the control of the cardiomyocyte-specific MLC260 promoter. For in vivo gene transfer, we chose AAV9 vectors at a dose of 3 × 10 12 viral genomes per mouse and initially tested application via intravenous administration, since this strategy has already been described to achieve homogeneous and effective  [3,14,21,34,41,43].
In a first series of experiments, an ssAAV genome was used, which contained the shRNA miR30 -tandem construct. TRPM4 knockdown efficiency was less than 50%, 11 weeks after AAV9 application. Since this degree of reduction is probably too low to expect an increased cardiac contractility, various features of the AAV-shRNA construct were further optimized. We aimed to enhance knockdown efficiency by the use of scAAV vectors which can achieve a faster and more efficient expression of the transgenic cassette [25]. Because scAAVs allow only reduced packaging capacity, we had to remove the expression reporter (tdTomato) as well as the WPRE sequence so that the transgene cassette was reduced to the promoter, the shRNA m i R -tandem, and the polyadenylation sequence.
Furthermore, an increase in the expression level of the shRNA miR30 -tandem should be achieved by using the CMV RNA Pol II promoter. Compared to promoters derived from cardiomyocytes, the CMV promoter mediates a significantly higher expression level in the mouse myocardium [6,27,34]. However, the degree of TRPM4 downregulation using this shRNA miR30 -tandem construct in the scAAV backbone under the control of the CMV promotor was also only in the range of 50% after 11 weeks, and slightly improved (~60%) when evaluated 16 weeks after vector application, supporting the idea that extending the life-span period is beneficial. In addition to the shRNAmiR30 RNAi approach, a classical shRNA design was developed as an alternative RNAi approach and tested directly in vivo without prior in vitro evaluation. However, the analysis of the shRNA-triple construct did not increase the TRPM4 knockdown efficiency compared to the previous ssAAV-shRNA miR30 -tandem vector. Due to concerns about shRNA toxicity and the restriction to expression from RNA Pol III promoters, no further test groups were treated with the classic shRNA-triple vector in order to increase the TRPM4 knockdown.
Since the knockdown potential of shRNA-#4 was in the range of 90% in B16F10 cells, we reasoned that the lower knockdown efficiency in the heart observed so far might result from inefficient delivery to the heart and cardiomyocytes by application to the peripheral circulation via the tail vein. We therefore tested whether injection via the retro-orbital sinus may lead to improved transduction efficiency with a given AAV9 vector. In a first experiment, we thus compared head to head the application via the retro-orbital sinus with injections via the lateral tail vein and found 2-fold more AAV viral copies per host genome with the application route via the retro-orbital sinus. This result strengthens the hypotheses that the injection via the retro-orbital sinus improves cardiac AAV9 transduction by allowing the vector solution to reach the heart more directly without significant dilution in the circulation. The reduced transduction efficiency in the liver observed with injection via the retro-orbital route is an additional argument for this hypothesis. Since the retro-orbital injection can already be carried out accurately in 3-week-old mice, juvenile mice were used in order to minimize the distribution volume of the vector solution as much as possible although it has been reported that the AAV vector transduction is more stable in adult animals [12]. Indeed, a~90% reduction in TRPM4 protein expression was achieved with the latter approach.
Given that no more than 90% reduction in the ventricle was obtained by Cre-loxP-mediated gene deletion in a cardiomyocyte-specific knockout mouse, it can be assumed that the improved AAV9-shTRPM4 miR30 -tandem-induced knockdown of TRPM4 in cardiomyocytes should be close to 100%. This result suggests that the retro-orbital application route in combination with the small distribution volume of juvenile mice achieves an improved AAV9 transfer into the heart of the animals and consequently leads to an increased cardiac TRPM4 knockdown. This gene silencing strategy can now be used to treat preclinical mouse models of acute and chronic systolic heart failure in order to restore cardiac contractile function.
Taken together, we have successfully developed a highly efficient AAV9-mediated RNAi strategy to achieve a vectorinduced knockdown of TRPM4 in the adult mouse heart. Combining the robust AAV9-shRNA miR30 design with an optimal route of application yielded a 90% reduction of TRPM4 Fig. 5 AAV9 application via the retro-orbital sinus elevates cardiac transduction efficiency and results in efficient scAAV9-CMV-shTRPM4 miR30 -tandem-mediated TRPM4 knockdown in the moue heart. a Comparison of the intravenous AAV9 application methods via the tail vein (sv) and the retro-orbital sinus (ro) of the mouse. b Schematic representation of the experimental course. c-g Determination of AAV9 transduction efficiency using droplet digital PCR (ddPCR). Droplet count view for c viral genomes and d host genomes in hearts injected via tail vein or retro-orbital sinus. Positive droplets are displayed in blue (viral genome counts of the AAV containing bGHpA, bovine growth hormone polyadenylation signal sequence) or green (host genome counts of the Magel2 reference gene) and negative droplets in black. AAV9 transduction efficiency was quantified as viral genomes/host genome in the e heart, f liver, and g skeletal muscle (musculus vastus lateralis). h Schematic representation of the scAAV-CMV-shTRPM4 miR30 -tandem and scAAV9-CMV-GFP control vector used. i Analysis of TRPM4 expression followed 16 weeks after AAV9 application. j Western blot analysis with anti-TRPM4 and anti-GAPDH antibodies of ventricular microsomal membrane fractions. Single lanes represent myocardial protein fractions of individual mice. k Quantification of the relative TRPM4 protein in hearts of scAAV9-CMV-TRPM4 miR30 -tandem-treated mice compared to AAV9-CMV-GFP treated controls. Relative expression of TRPM4 is expressed as mean ± SD. *p <0.05, ***p <0.005 in the mouse myocardium. This strategy represents a promising approach to test whether TRPM4 knockdown leads to an increase in inotropic response in healthy animals and particularly in heart failure models. If successful, the strategy could be transferred to patients with heart failure associated with elevated catecholamine levels.
Acknowledgements Open Access funding enabled and organized by Projekt DEAL. We are thankful to Stefan Offermanns (Max-Planck-Institute for Heart and Lung Research, Germany) who kindly provided the αMHC/CreERT2 mice, and to Christin Richter, Manuela Ritzal, Hans-Peter Gensheimer, and the team from the Interfakultäre Biomedizinische Forschungseinrichtung (IBF) from the Heidelberg University for the expert technical assistance.
Author contribution Rebekka Medert: conceptualization, data curation, formal analysis, validation, investigation, visualization, writing-original draft, writing-review and editing Andreas Jungmann: conceptualization, methodology, writingreview and editing Staffan Hildebrand: methodology, lentivirus production, writingreview and editing Dirk Grimm: conceptualization, methodology, writing-review and editing Veit Flockerzi: methodology, TRPM4 antibody, writing-review and editing Oliver J. Müller: conceptualization, methodology, writing-review and editing Martin Busch: conceptualization, methodology, writing-review and editing Patrick Most: conceptualization, methodology, supervision, writingreview and editing Dagmar Schumacher: conceptualization, formal analysis, supervision, validation, investigation, writing-review and editing Marc Freichel: conceptualization, formal analysis, supervision, funding acquisition, investigation, writing-original draft, project administration, writing-review and editing Data and materials availability All data that support the findings of this study are available in this study within the manuscript and/or its supplementary materials.

Declarations
Competing interests Patrick Most, Martin Busch, and Dirk Grimm are co-founders and shareholders of the company AaviGen GmbH. All other authors declare no conflict of interest.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.